Cyclerion Therapeutics (NASDAQ:CYCN) Issues Quarterly Earnings Results

Cyclerion Therapeutics (NASDAQ:CYCN) announced its earnings results on Tuesday. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.10) by $6.69, FiscalAI reports. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 62.10%.

Cyclerion Therapeutics Stock Up 0.9%

CYCN stock traded up $0.03 during midday trading on Tuesday, reaching $3.52. The stock had a trading volume of 6,374 shares, compared to its average volume of 2,590,489. The firm has a market cap of $16.47 million, a price-to-earnings ratio of -2.59 and a beta of 1.76. The business has a fifty day simple moving average of $3.37 and a two-hundred day simple moving average of $2.60. Cyclerion Therapeutics has a twelve month low of $1.03 and a twelve month high of $8.48.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cyclerion Therapeutics in a report on Friday, July 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Institutional Trading of Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP purchased a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 75.62% of the company’s stock.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.